RAIN
Closed
Rain Therapeutics Inc
3.07
+0.07 (+2.33%)
Last Update: 01 Jul 2025 23:00:00
Yesterday: 3.
Day's Range: 2.85 - 3.21
Send
sign up or login to leave a comment!
When Written:
8.07
Rain Therapeutics Inc is a clinical-stage biotechnology company that focuses on developing precision therapies for cancer patients. The company was founded in 2017 and is headquartered in Newark, California, USA. Rain Therapeutics' approach is to identify and target specific genetic mutations and alterations that drive cancer growth.
The company's lead product candidate, RAIN-32, is a small molecule inhibitor that targets the SHP2 protein, which is involved in cancer cell growth and survival. RAIN-32 is currently in Phase 2 clinical trials for the treatment of solid tumors with specific genetic mutations.
Rain Therapeutics also has a pipeline of other precision oncology therapies in development, including RAIN-10, which targets a genetic mutation found in certain types of lung cancer.
The company has partnerships with several academic institutions and biotechnology companies to advance its research and development efforts. Rain Therapeutics is committed to improving the lives of cancer patients by developing innovative and effective therapies.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
The company's lead product candidate, RAIN-32, is a small molecule inhibitor that targets the SHP2 protein, which is involved in cancer cell growth and survival. RAIN-32 is currently in Phase 2 clinical trials for the treatment of solid tumors with specific genetic mutations.
Rain Therapeutics also has a pipeline of other precision oncology therapies in development, including RAIN-10, which targets a genetic mutation found in certain types of lung cancer.
The company has partnerships with several academic institutions and biotechnology companies to advance its research and development efforts. Rain Therapeutics is committed to improving the lives of cancer patients by developing innovative and effective therapies.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
(0)
(0)
Send
sign up or login to leave a comment!!








